It was a short run, but Biogen and AbbVie’s multiple sclerosis-fighter Zinbryta is coming off markets around the globe. The pair revealed the decision on Friday, citing safety concerns and adding that “it is in the best interest of patients to voluntarily withdraw worldwide marketing authorizations” for the drug, which won FDA approval in May 2016.Original Article
Biogen, AbbVie yank underperforming MS drug Zinbryta after encephalitis reports
